Acquiring Company
XOMA Royalty Corporation
Acquired Company
Generation Bio
Description
On February 9, 2026, XOMA Royalty completed a cash merger with Generation Bio Co., paying USD 4.2913 per share. This transaction led to Generation Bio being delisted from Nasdaq, marking its transition to a wholly owned subsidiary of XOMA Royalty. The merger included a contingent value right aimed at providing potential additional payments linked to acquired assets.
Fundz sees it the moment XOMA Royalty Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Generation Bio?
Generation Bio was acquired by XOMA Royalty Corporation, based in Emeryville. The deal was reported on October 4, 2026. XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty Corporation is privately held and operates in Biotechnology.
When did XOMA Royalty Corporation acquire Generation Bio?
XOMA Royalty Corporation's acquisition of Generation Bio was reported on October 4, 2026. On February 9, 2026, XOMA Royalty completed a cash merger with Generation Bio Co., paying USD 4.2913 per share. This transaction led to Generation Bio being delisted from Nasdaq, marking its transition to a wholly owned subsidiary of XOMA Royalty. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Generation Bio do?
Generation Bio is a biotechnology company changing what is possible for people living with T cell-driven autoimmune diseases. It is privately held, operating in Manufacturing, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.